Newswise — Optimized iPSC-derived NK (iNK) cells have been developed for on-demand cancer immunotherapy. Here, Cichocki and colleagues describe a triple-gene-edited iNK cell product, termed iADAPT NK, which persists and functions in vivo in the absence of exogenous cytokines and can be combined with therapeutic antibodies for enhanced tumor targeting.

Other Link: DOI link Other Link: Publisher Website Other Link: Download PDF

Register for reporter access to contact details

DOI link; Publisher Website; Download PDF